



# DBCG NACT Seminar

## 4. & 5. november 2019

Maj-Britt Jensen  
DBCG's sekretariat

# NACT

## Retningslinjer Kapitel 7


### Neoadjuverende kemoterapi ved brystkræft mhp. down-sizing og down-staging

4. oktober 2016


NACT kan tilbydes patienter, der vurderes at være kandidater til adjuverende kemoterapi, og som har klinisk tumorstadiet klassificeret som T2: (2,0 cm < tumor ≤ 5.0 cm), N0-N1 og histologisk påvist invasivt c. mammae af ikke-lobulær type.

# Patient population 2016-2018


## Primært operable




# Ekskluderede patienter




# Primært operable




# Protokol allokering, 2016-2018



# DBC G B,D KT




# KT 2016-2018 pr kirurgisk afdeling







# KT 2016-2018 pr kirurgisk afdeling




# År, afd Region H, Sj




# Region S




# Region M, N



# KT 2016-2018 tumorstørrelse (UL/Mik)




# KT 2016-2018 tumorstørrelse (UL/Mik)




21-50 mm	NEO	Up Front S	
2016	209	702	23%
2017	316	615	34%
2018	389	526	43%

# KT 2016-18, HER2 ER




# KT 2016-18, HER2 ER






# HER2 ER


	ER-	ER+
2016	23%	13%
2017	29%	20%
2018	38%	26%



# HER2 ER, 2-5 cm




# KI67 %




2016 42%  
2017 31%  
2018 37%


# Histologisk type




# Operationstype




# Operationstype



# Tumordiameter (UL) efter NACT



# SN anvendt up front






# NACT: Responsgrad

Responsegrad (Miller-Payne)

Gradering af respons efter neoadjuverende behandling:

- Responsgrad 1: Ingen forekomst af invasive tumorceller (der må godt være tilstedeværelse af DCIS).
- Responsgrad 2: Mere end 90 % tab af tumorceller.
- Responsgrad 3: Mellem 30 og 90 % tab af tumorceller.
- Responsgrad 4: Mindre end 30 % tab af tumorceller.

# NACT: Responsgrad



# Behandlingsrespons, lymfeknuder

Antal med metastaser og behandlingsrespons

Antal uden metastaser men med behandlingsrespons

2016: 22% uoplyst

2017: 7% uoplyst

2018: 9% uoplyst

2017		U metastaser	
M metastaser		0	1+
	0	265	82
	1+	58	35

2018		U metastaser	
M metastaser		0	1+
	0	320	114
	1+	82	42

# Medicinsk behandling, indberetning flow

ÅR	-	+	%
2016	490	1645	23
2017	536	1541	26
2018	657	1409	32

TYPE	-	+	%
NEO	395	1018	28
UFS	1288	3577	26

NB Off-study, Q4 2018

AFD	-	-K	+	%
RH	75	66	576	10/9
HE	34	588	354	3/60
HI	11		211	5
BO	3		25	11
NÆ	519	242	189	55/25
OUH	16	5	461	3/1
SØ	23	3	235	9/1
ES	43	1	220	16/0
VE	3	12	443	1/3
AAR	3	16	716	0/2
HERN	5	5	572	1/1
AAL	1	7	593	0/1
	746	945	4595	

# Medicinsk behandling, indberetning flow

ÅR	-	+	%	
2016	490	1645	23	27
2017	536	1541	26	30
2018	657	1409	32	45

TYPE	-	+	%
NEO	395	1018	28
UFS	1288	3577	26

NB Off-study, Q4 2018

AFD	-	-K	+	%
RH	75	66	576	10/9
HE	34	588	354	3/60
HI	11		211	5
BO	3		25	11
NÆ	519	242	189	55/25
OUH	16	5	461	3/1
SØ	23	3	235	9/1
ES	43	1	220	16/0
VE	3	12	443	1/3
AAR	3	16	716	0/2
HERN	5	5	572	1/1
AAL	1	7	593	0/1
	746	945	4595	

# NACT RT

	2016	2017	2018
BCS	138	217	333
BIOPSI	14	25	68
M	180	229	210
M, N+	83	88	85
ITT RT	230	320	438
RTG +	194	275	355
RTG -	2	1	1
RTG ?	34	44	82